The global molecular diagnostics market is undergoing a seismic shift. Driven by the increasing prevalence of infectious diseases, chronic conditions, and a surge in personalized medicine, the demand for Custom OEM Molecular Testing Technology has never been higher. Healthcare providers and laboratory networks are transitioning from generalized diagnostic tools to high-specificity, rapid-response molecular systems that integrate Real-Time PCR, Next-Generation Sequencing (NGS), and Point-of-Care Testing (POCT) capabilities.
For multinational medical enterprises, the procurement criteria have evolved. It is no longer just about the cost-per-test; it is about the Information Gain provided by the technology. Leading manufacturers like Ningbo Medvok Medical Co., Ltd. are now serving as strategic partners rather than just vendors, offering end-to-end integration from raw material synthesis (antigens/antibodies) to the deployment of automated diagnostic platforms.
Ningbo Medvok Medical Co., Ltd. is a high-tech biotechnology company focused on the R&D and production of antigens, antibodies and downstream detection reagents for diagnosis and therapy. The product pipelines cover cardiovascular and cerebrovascular, inflammation, infectious diseases, tumors, hormones and other categories, from raw materials to finished products.
Innovation is in our DNA! Bioantibody keeps developing new technologies. Currently, our products have been delivered to more than 60 countries and cities worldwide. Using the ISO 13485 management system, the product quality is greatly trusted by customers. With the mission [Biotech For A Better Life], we are committed to innovation and providing our best solutions to our customers. We sincerely believe we could make our special contribution to human ecology and health.
Core development of high-affinity recombinant proteins.
Comprehensive PCR and Immunoassay system integration.
Logistics and regulatory support for 60+ countries.
Commitment to sustainability and human rights.
As we look toward 2030, the molecular testing landscape is moving toward "Total Automation and Decentralization". Our R&D roadmap focuses on three critical technological pillars:
This roadmap is designed to bridge the gap between high-end laboratory research and practical, clinical application. By leveraging our deep expertise in antibody production and fluorescent probe assays, we provide our OEM partners with a future-proof technological foundation.
Our role as a Custom OEM Manufacturer extends beyond the production line. We provide macro-level solutions tailored to the specific needs of various sectors:
Hospital-grade PCR systems and automated analyzers for high-throughput testing.
GMP-certified solutions for livestock health, such as Florfenicol oral solutions and pathogen test kits.
Self-testing kits (Ovulation, Antigen) designed for user-centric accuracy and ease of use.
Compliance & Localization: Navigating the regulatory landscape of the EU (CE-IVDR), USA (FDA), and emerging markets requires a partner with deep compliance knowledge. Medvok ensures all OEM products meet local registration requirements, providing technical dossiers and clinical trial data to accelerate market entry.
As an IVD solutions provider, we have worked and will keep working intensively to support research and foment knowledge and prevention of the diseases. For us, a well-informed society is a healthier society. We care about protecting the human health and hope all of society to have access to clean, affordable, and reliable biotechnologies.
Furthermore, our economic development will be compatible with proper conduct in relation to ethics, society, the workplace, the environment and respect for human rights. We think of society as a group of individuals with equal rights and opportunities. In order to materialize this commitment, we have developed the sustainability policy on environmental and social matters.
Medvok Medical
